Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 2Other hematologic neoplasm 2CNS 2Other 1Lymphoid 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Brain Neoplasms 2

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Ipilimumab 36Lomustine 35Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Oxygen × CNS × Clear all
NCT05904704 2025-11-14

Oxygen-Enhanced MRI for Generating Hypoxia Maps in Patients With Intracranial Tumors

OHSU Knight Cancer Institute

Phase NA Withdrawn
CNS

Brain Neoplasms

NCT03649880 2025-03-25

Feasibility of FMISO in Brain Tumors

OHSU Knight Cancer Institute

Phase 2 Recruiting
50 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡